Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 26 , ISSUE 1 ( January, 2022 ) > List of Articles

Original Article

Descriptive Epidemiology of COVID-19 Deaths during the First Wave of Pandemic in India: A Single-center Experience

Prakash Tendulkar, Pragya Pandey, Prasan K Panda, Ajeet S Bhadoria, Poorvi Kulshreshtha

Keywords : Coronavirus disease 2019, Mortality, Risk factors

Citation Information : Tendulkar P, Pandey P, Panda PK, Bhadoria AS, Kulshreshtha P. Descriptive Epidemiology of COVID-19 Deaths during the First Wave of Pandemic in India: A Single-center Experience. Indian J Crit Care Med 2022; 26 (1):71-75.

DOI: 10.5005/jp-journals-10071-24085

License: CC BY-NC 4.0

Published Online: 17-01-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Background: With the looming threat of recurrent waves of coronavirus disease-2019 (COVID-19) in the presence of mutated strains, it is of paramount importance to understand the demographic and clinical attributes of COVID-19 related mortalities in each pandemic wave. This could help policy makers, public health experts, and clinicians to better plan preventive and management strategies to curb COVID-19 related mortality. Materials and methods: This was a hospital record-based, retrospective cross-sectional descriptive study, at a tertiary care hospital in Rishikesh, India. The study included all deceased patients between March 2020 and January 2021 (first wave) who had tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription polymerase chain reaction (RT-PCR) and were hospitalized. The study was done to describe demography, clinical presentation, laboratory parameters, treatment given, and associated complications of all COVID-19 deaths. Result: Out of 424 mortalities, 298 (70.38%) were males and 126 (29.62%) were females. Mean age of patients was 55.85 ± 16.24 years, out of which 19.5% were less than 45 years old, 33.6% were 45–60 years old, and 41.8% were more than 60 years old. Comorbidity in the form of type II diabetes mellitus was present in 41.4% [95% CI (41.4–51.1)], hypertension in 39.8% [95% CI (35.1–44.6)], and coronary artery disease (CAD) in 15.2% [95% CI (11.8–18.8)]. At the time of presentation, shortness of breath was present in 73.6% [95% CI (69.1–77.7)], fever in 64.92% [95% CI (60.1–69.4)], and cough in 46.1%, [95% CI (41.1–50.8)]. Deranged laboratory parameters were lymphopenia in 90.2% [95% CI (86.8–92.7)], transaminitis in 59.7% [95% CI (54.8–64.3)], and hypercreatinemia in 37.7% [95% CI (33.1–42.5)]. Complications manifested were acute respiratory distress syndrome (ARDS) in 78.3% [95% CI (74–82.1)] and shock in 54.7% [95% CI (49.8–59.5)]. Median time duration between onset of symptom and hospital admission was 5 days (interquartile range (IQR) = 3–5 days) and median length of hospital stay was 9 days (IQR = 4–14 days). Conclusion: During the first pandemic wave, COVID-19 related mortality was 2.37 times higher among males, 2.14 times in the age group >60 than <45 years. The most common associated comorbidities (>40%) were type II diabetes mellitus and hypertension. The most common associated symptoms (>60%) were shortness of breath and fever. Lymphopenia was seen in >90% cases while liver involvement in 60% and kidney in 38% cases. Median hospital stay was doubled the prehospital illness.


HTML PDF Share
  1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382(18): 1708–1720. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7092819/.
  2. Thai PQ, Toan DTT, Dinh TS, Hoang TH Van, Luu NM, Xuan Hung L, et al. Factors associated with the duration of hospitalization among COVID-19 patients in Vietnam: a survival analysis. Epidemiol Infect 2020;148:e114. DOI: 10.1017/S0950268820001259. Available from: https://pubmed.ncbi.nlm.nih.gov/32517822/.
  3. Wortham JM. Characteristics of persons who died with COVID-19– United States, February 12–May 18, 2020. MMWR Morb Mortal Wkly Rep 2020;69(28):923–929. DOI: 10.15585/mmwr.mm6928e1. Available from: https://www.cdc.gov/mmwr/volumes/69/wr/mm6928e1.htm.
  4. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323(18): 1775–1776. DOI: 10.1001/jama.2020.4683. Available from: https://jamanetwork.com/journals/jama/fullarticle/2763667.
  5. Bienvenu LA, Noonan J, Wang X, Peter K. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res 2020;116(14):2197. DOI: 10.1093/cvr/cvaa284. Available from: https://academic.oup.com/cardiovascres/article/116/14/2197/5924554.
  6. Kapoor M, Agrawal D, Ravi S, Roy A, Subramanian SV, Guleria R. Missing female patients: an observational analysis of sex ratio among outpatients in a referral tertiary care public hospital in India. BMJ Open 2019;9(8). DOI: 10.1136/bmjopen-2018-026850.
  7. Moreno-Torres V, de la Fuente S, Mills P, Muñoz A, Muñez E, Ramos A, et al. Major determinants of death in patients hospitalized with COVID-19 during the first epidemic wave in Madrid, Spain. Medicine (Baltimore) 2021;100(16):e25634. DOI: 10.1097/MD.0000000000025634. Available from: https://journals.lww.com/md-journal/Fulltext/2021/04230/Major_determinants_of_death_in_patients.88.aspx.
  8. Biswas M, Rahaman S, Biswas TK, Haque Z, Ibrahim B. Association of sex, age, and comorbidities with mortality in COVID-19 patients: a systematic review and meta-analysis. Intervirology 2021;64(1):36–47. DOI: 10.1159/000512592. Available from: https://www.karger.com/Article/FullText/512592.
  9. Nandy K, Salunke A, Pathak SK, Pandey A, Doctor C, Puj K, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr Clin Res Rev 2020;14(5):1017–1025. DOI: 10.1016/j.dsx.2020.06.064. Available from: https://pubmed.ncbi.nlm.nih.gov/32634716/.
  10. Badedi M, Darraj H, Alnami AQ, Makrami A, Mahfouz MS, Alhazmi K, et al. Epidemiological and clinical characteristics of deceased COVID-19 patients. Int J Gen Med 2021;14:3809–3819. DOI: 10.2147/IJGM.S320713. Available from: https://www.dovepress.com/epidemiological-and-clinical-characteristics-of-deceased-covid-19-pati-peer-reviewed-fulltext-article-IJGM.
  11. Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health 2020;65(5):533–546. DOI: 10.1007/s00038-020-01390-7. Available from: https://pubmed.ncbi.nlm.nih.gov/32451563/.
  12. Lee J, Park S-S, Kim TY, Lee D-G, Kim D-W. Lymphopenia as a biological predictor of outcomes in COVID-19 patients: a nationwide cohort study. Cancers (Basel) 2021;13(3):1–15. DOI: 10.3390/cancers13030471. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865511/.
  13. Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol 2020;35(8): 763–773. DOI: 10.1007/s10654-020-00678-5. Available from: https://pubmed.ncbi.nlm.nih.gov/32816244/.
  14. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020;506:145–148. DOI: 10.1016/j.cca.2020.03.022. Available from: https://pubmed.ncbi.nlm.nih.gov/32178975/.
  15. Hansrivijit P, Gadhiya KP, Gangireddy M, Goldman JD. Risk factors, clinical characteristics, and prognosis of acute kidney injury in hospitalized COVID-19 patients: a retrospective cohort study. Medicines 2021;8(1):4. DOI: 10.3390/medicines8010004. Available from: https://pubmed.ncbi.nlm.nih.gov/33430296/.
  16. Lin L, Wang X, Ren J, Sun Y, Yu R, Li K, et al. Risk factors and prognosis for COVID-19-induced acute kidney injury: a meta-analysis. BMJ Open 2020;10(11). DOI: 10.1136/bmjopen-2020-042573. Available from: https://pubmed.ncbi.nlm.nih.gov/33172950/.
  17. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol 2021;32(1):151–160. DOI: 10.1681/ASN.2020050615. Available from: https://jasn.asnjournals.org/content/32/1/151.
  18. Zhong Z, Li H, Zhu J, Ji P, Li B, Pang J, et al. Clinical characteristics of 2,459 severe or critically ill COVID-19 patients: a meta-analysis. Medicine (Baltimore) 2021;100(5):e23781. DOI: 10.1097/MD.0000000000023781. Available from: https://pubmed.ncbi.nlm.nih.gov/33592834/.
  19. Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis 2020 201 2020;20(1):1–12. DOI: 10.1186/s12879-020-05371-2. Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05371-2.
  20. Asirvatham ES, Sarman CJ, Saravanamurthy SP, Mahalingam P, Maduraipandian S, Lakshmanan J. Who is dying from COVID-19 and when? An analysis of fatalities in Tamil Nadu, India. Clin Epidemiol Glob Heal 2021;9:275. DOI: 10.1016/j.cegh.2020.09.010. Available from: https://pubmed.ncbi.nlm.nih.gov/33043168/.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.